Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized
thrombocytopenia.
Splenectomy is the standard treatment for patients who fails the first-line treatment:
corticosteroid. Rituximab, has recently emerged as a promising treatment for ITP. The aim of
the study is to determine whether early treatment with Rituximab can result in durable
remissions, and consequently, lead to the avoidance of splenectomy in a significant number of
patients.
Phase:
Phase 3
Details
Lead Sponsor:
Ostfold Hospital Trust
Collaborators:
Oslo University Hospital South-Eastern Regional Health Authority